Genetic Technologies Limi... (GENE)
Genetic Statistics
Share Statistics
Genetic has 145.42M shares outstanding. The number of shares has increased by 75.32% in one year.
| Shares Outstanding | 145.42M |
| Shares Change (YoY) | 75.32% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 27.94M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.78 and the forward PE ratio is null. Genetic's PEG ratio is 0.01.
| PE Ratio | -0.78 |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| Forward PS | null |
| PB Ratio | 5.1 |
| P/FCF Ratio | -0.96 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Genetic.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.48.
| Current Ratio | 0.88 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | -0.09 |
| Interest Coverage | -126.64 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $139.36K |
| Profits Per Employee | $-218.49K |
| Employee Count | 55 |
| Asset Turnover | 1.24 |
| Inventory Turnover | 18.21 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.48, so Genetic's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.48 |
| Relative Strength Index (RSI) | 47.23 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Genetic had revenue of 7.66M and earned -12.02M in profits. Earnings per share was -0.09.
| Revenue | 7.66M |
| Gross Profit | 3.9M |
| Operating Income | -6.54M |
| Net Income | -12.02M |
| EBITDA | -11.43M |
| EBIT | -11.97M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 1.02M in cash and 875.19K in debt, giving a net cash position of 145.42K.
| Cash & Cash Equivalents | 1.02M |
| Total Debt | 875.19K |
| Net Cash | 145.42K |
| Retained Earnings | -166.38M |
| Total Assets | 6.19M |
| Working Capital | -500.09K |
Cash Flow
In the last 12 months, operating cash flow was -9.68M and capital expenditures -32.97K, giving a free cash flow of -9.71M.
| Operating Cash Flow | -9.68M |
| Capital Expenditures | -32.97K |
| Free Cash Flow | -9.71M |
| FCF Per Share | -0.07 |
Margins
Gross margin is 50.94%, with operating and profit margins of -85.29% and -156.78%.
| Gross Margin | 50.94% |
| Operating Margin | -85.29% |
| Pretax Margin | -156.78% |
| Profit Margin | -156.78% |
| EBITDA Margin | -149.13% |
| EBIT Margin | -85.29% |
| FCF Margin | -126.71% |
Dividends & Yields
GENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for GENE.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 14, 2023. It was a backward split with a ratio of 1:5.
| Last Split Date | Dec 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -42.11 |
| Piotroski F-Score | 4 |